Back to search

Peptide record

TPDB43113

FLAK-120G Anticancer standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43113
FLAK-120G
Anticancer
Cancer-related peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF
standard
No
A 11-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
VALALKALKKL-NH2
Physicochemical Analysis
C56H106N14O12
RNDCEQGHIMFPSTWY
L
1167.54
10.84
3
0
8
+3
0.29
1.191
195.45
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
4
L
3
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 4 K: 3 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
11
C56H106N14O12
1167.54
10.84
+3
0.29
1.191
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =950 µg/ml
Anticancer
950 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =600 µg/ml
Anticancer
600 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =770 µg/ml
Anticancer
770 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =>1000 µg/ml
Anticancer
>1000 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =>1000 µg/ml
Anticancer
>1000 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =760 µg/ml
Anticancer
760 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2